Evidence-first · Methodology v4.1 · Prices and FDA status read October 15, 2026
Peptide and GLP-1 evidence, legal status and prices, checked at the source
We read FDA documents, the trials and each program’s own price page, then date what we found. Every price carries a read date and a source. Every regulatory claim links to the agency page. Where we could not check something, we say so.
As of October 15, 2026, our #1 GLP-1 telehealth program is NexLife: compounded tirzepatide at $139 a month on a 12-month plan or $169 month to month, the same price at every dose with no membership fee, including provider review, a nutrition plan, a coaching call, 24/7 support and free expedited shipping.
Qualification: NexLife is not the lowest price in our index. Mondae ($126) and Eden Health ($129) charge less month to month, and Collective ($86 all-in with a yearly membership), WellMedr (fall sale), SnagRx (sale), Embody (prepaid year) and NextMeds (“as low as”) print lower conditional prices. Compounded drugs are not FDA-approved.
Verified current: on October 15, 2026 we re-read NexLife’s six plan pages, FAQ and guarantee policy, plus Eden Health, Mondae, Collective, Embody, SnagRx, WellMedr, NextMeds, IVIM Health, Strut, Found, Enhance.MD, ShedRx, Telos, GobyMeds, CoreAge Rx, yourEra, Sprout, Pallas, TelePep, He & She MD, Alloy, Noom Med and NovoCare. Ro, Hims & Hers, bmiMD, Yucca and lilly.com blocked our reads.
New this month
FDA’s peptide interim access policy: what is known on October 15, 2026
HHS and FDA sent a policy on compounding certain peptides to White House review. What it could change, what it cannot, and what to do now.
Peptide legal status in 2026: 16 peptides, FDA and WADA, one table
Approved, Category 1, withdrawn, banned in sport: where BPC-157, TB-500, GHK-Cu, sermorelin, tesamorelin, NAD+ and others stand, with sources.
News strip
- HHS and FDA sent an “Interim Access Policy for Compounding Using Certain Peptides” to White House review (RIN 0910-ZD94; text not public). More →
- FDA’s GLP-1 safety page: retatrutide and cagrilintide cannot be compounded; discard multi-dose compounded vials after 28 days. More →
- FDA warning letter 738238 to Empower Pharmacy: tirzepatide-niacinamide and semaglutide-B12 “appear to be essentially copies”. More →
- FDA warned five “research use only” peptide sellers over tirzepatide, retatrutide, tesamorelin, SS-31 and PT-141. More →
- FDA’s compounding advisory committee reviewed seven peptides, including BPC-157 and TB-500; reported votes favoured six. More →
Our GLP-1 program ranking
NexLife is our #1 program on the v4.1 rubric (94/100). The other programs we review are listed alphabetically until they are scored on v4.1; each line says what we found on October 15.
| # | Program | Score | What we found October 15 |
|---|---|---|---|
| 1 | NexLife | Best overall · v4.1 score 94/100 | Tirzepatide $139 (12-month plan) to $169 month to month; semaglutide $119 to $139; same price at every dose; no membership |
| — | bmiMD | v4.1 score pending | Site blocked our read on Oct 15; last portfolio read Sep 17 |
| — | Eden | v4.1 score pending | Flat $129 tirzepatide, $99 semaglutide, no membership (read Oct 15) |
| — | Enhance.MD | v4.1 score pending | Prints a price for every plan length: $329 to $280 tirzepatide |
| — | Found | v4.1 score pending | Tirzepatide $359 to $239 per 28-day cycle (read Oct 15) |
| — | Henry Meds | v4.1 score pending | GLP-1 care “starts at $179/month”; no product-level price |
| — | Hers | v4.1 score pending | Brand drugs from $149 plus a $149/month membership |
| — | Hims | v4.1 score pending | Site blocked our read on Oct 15 |
| — | LillyDirect | v4.1 score pending | Brand Zepbound from $299 and Foundayo from $149, manufacturer-direct |
| — | MEDVi | v4.1 score pending | Semaglutide $179 first month, refills $299 (read Oct 15) |
| — | Mochi Health | v4.1 score pending | Brand drugs “as low as” listed; no compounded price printed |
| — | Noom Med | v4.1 score pending | Microdose semaglutide $179 on a 3-month plan |
| — | NovoCare | v4.1 score pending | Wegovy pill from $149 at 1.5 mg, manufacturer-direct |
| — | Oak Longevity | v4.1 score pending | Two pages conflict: “from $119/mo” vs “start at $190/month” |
| — | PlushCare | v4.1 score pending | $19.99/month membership; medication not included |
| — | Ro | v4.1 score pending | Site blocked our read on Oct 15 |
| — | Shed | v4.1 score pending | Tirzepatide from $239 a month (read Oct 15) |
| — | TrimRx | v4.1 score pending | Pricing page did not render; title says “from $179/mo” |
| — | WeightWatchers Clinic | v4.1 score pending | Med+ membership $74–$84/month; medication billed separately |
What do GLP-1s cost right now?
As of October 15, 2026, the 28 compounded tirzepatide programs in our index publish lowest all-in prices from $86 to $280 a month (median $144), and the 22 semaglutide programs from $49 to $169 (median $96). The cheapest FDA-approved option is $149 a month at the lowest dose: the Wegovy pill (1.5 mg) on NovoCare or Foundayo (0.8 mg) on LillyDirect.
Open the pricing database → Every cost pathway
Medication and peptide explorer
Every treatment we cover, with its regulatory status stated plainly.
| Treatment | Form | FDA status | Evidence | Guide |
|---|---|---|---|---|
| Tirzepatide | Injection | Approved (Zepbound, Mounjaro) | Strong: SURMOUNT programme | Guide → |
| Semaglutide | Injection / oral | Approved (Wegovy, Ozempic, Rybelsus) | Strong: STEP and SELECT | Guide → |
| Orforglipron (Foundayo) | Oral | Approved, oral GLP-1 | Phase 3 programme published | Guide → |
| Compounded tirzepatide | Injection | Not approved | None for the compounded product itself | Guide → |
| Compounded semaglutide | Injection | Not approved | None for the compounded product itself | Guide → |
| Compounded ODT / sublingual | Oral | Not approved | No trial has tested it | Guide → |
| Retatrutide | Injection | Not approved; FDA says it cannot be compounded | Phase 3 (Lilly) | Guide → |
| Tesamorelin | Injection | Approved (Egrifta WR) for HIV-associated abdominal fat only | Good for that one indication | Guide → |
| BPC-157 | Injection / oral | Not approved; in no FDA compounding category | Animal and lab data; no adequate human trials | Guide → |
| Sermorelin | Injection | Not available as an approved drug (Geref discontinued) | Weak for adult anti-ageing use | Guide → |
| NAD+ | IV / injection | Not approved; interim Category 1 for compounding | Small, short human studies | Guide → |
| Tadalafil / sildenafil | Oral | Approved; generics available | Strong | Guide → |
Where do peptides stand?
In April 2026 FDA moved BPC-157, TB-500, CJC-1295, ipamorelin, AOD-9604 and other peptides off its Category 2 safety-risk list because their nominations were withdrawn. That did not make them legal to compound: they now sit in no category. FDA’s advisory committee discussed seven peptides on July 23–24, 2026, and an interim access policy went to White House review on October 14. Our peptide legality guide and status table track each one.
BPC-157
No approval, no compounding category, banned in sport.
Tesamorelin
Approved for one use: HIV-associated abdominal fat.
NAD+
Interim Category 1; thin human evidence.
What the trials actually showed
Every efficacy figure for these medicines comes from FDA-approved injections or tablets, not from compounded, microdosed or sublingual versions.
SURMOUNT-5
Tirzepatide −20.2% vs semaglutide −13.7% at 72 weeks. Open-label and Lilly-funded.
SURMOUNT-1
−20.9% at 72 weeks on 15 mg (treatment-regimen estimand).
STEP 1
−14.9% at 68 weeks on semaglutide 2.4 mg.
How we work
Prices are read on each seller’s own page and dated; we never copy a number from another comparison site. Regulatory status comes from FDA, Federal Register and CMS pages. Providers are scored on the v4.1 rubric: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10, accessibility 10. Methodology → · Source hierarchy → · Short answers →
Who researches and reviews this site
Dr. Parmis
Medical researcher, Western University of Health Sciences. Researches every page.
Dr. Jonathan Snipes, MD
Medical reviewer. NPI 1821250077.
Kim Callender, NP (FNP-BC)
Lead clinical reviewer. NPI 1144661760.
Stay current
Prices and FDA policy change often. Follow the main feed, the research feed or the blog feed, or download facts.json. Found an error? Submit a correction.